Maciej Kazmierczak

Poznan, WP, Poland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.

Journal: British journal of haematology
Published: July 29, 2025

Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.

Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.

Journal: European journal of haematology
Published: August 14, 2024

Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.

Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.

Journal: British journal of haematology
Published: August 08, 2024

Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.

Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.

Journal: Leukemia research
Published: January 16, 2024

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.

Journal: Future oncology (London, England)
Published: December 13, 2023

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: December 13, 2022

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 17, 2022

Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Journal: Cancers
Published: July 15, 2022

Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia.

Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia.

Journal: Cancers
Published: May 08, 2021

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

Journal: The Lancet. Oncology
Published: May 21, 2020

Impact of the Q.Clear reconstruction algorithm on the interpretation of PET/CT images in patients with lymphoma.

Impact of the Q.Clear reconstruction algorithm on the interpretation of PET/CT images in patients with lymphoma.

Journal: EJNMMI research
Published: April 24, 2020

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Journal: Blood advances
Published: April 06, 2020
Showing 1-12 of 31

Last Updated: 09/26/2026